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Abstract
Aim To investigate the clinical significance of
Grave’s ophthalmopathy-specific quality of
life (GO-QOL) in Korean patients.
Methods A cross-sectional study was
conducted at the Department of
Ophthalmology, Yonsei University College of
Medicine, Seoul, Korea, on 98 consecutive
Grave’s ophthalmopathy (GO) patients. The
GO-QOL survey provided by Terwee and
colleagues and suggested by the European
group on Graves’ orbitopathy (EUGOGO)
was translated into Korean language and
distributed to study participants. Clinical
severity was judged by scores of the modified
NOSPECS classification, and inflammatory
activity was measured by a seven-point scale
of clinical activity score (CAS).
Results The mean GO-QOL scores were 73.7
(standard deviation (SD), 26) for visual
functioning, 61.9 (SD 26) for appearance, and
67.8 for total quality of life (QOL; SD 22). The
worse QOL scores for each part were
significantly associated with the higher
modified NOSPECS score and CAS after
adjusting for confounders such as age and sex
(Po0.05, respectively). In particular, decreased
QOL scores for visual function were
significantly correlated with a higher grade of
extraocular muscle involvement (Po0.05).
Lower QOL scores for appearance were
associated with more severe soft-tissue
involvement and proptosis (Po0.05,
respectively).
Conclusions GO-QOL suggested by
EUGOGO showed correlation with objective
clinical parameters. GO-QOL can be a simple
and effective tool in the evaluation of the clinical
and psychological illness of GO patients.
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Introduction
Grave’s ophthalmopathy (GO) is an
autoimmune-associated inflammatory disorder
of the orbit causing disfiguring proptosis, pain,
redness, and swelling of the eyelids, as well as
grittiness of the eyes, diplopia, and sometimes
even blindness.1,2 GO may be severely disabling
because of its effect on vision and appearance.
About 25–50% of patients with Grave’s thyroid
disease suffer from GO.3 The management of
GO has been well studied previously, but the
impaired quality of life (QOL) caused by GO
has been the focus of recent attention.4
QOL of patients with GO was investigated
using a health questionnaire (Medical Outcome
Study Short-Form General Health Survey and
Sickness Impact Profile) by Gerding et al.4 The
study showed little correlation between
measures of activity or severity of disease and
the scores on the QOL questionnaire. The
authors reported that patients with mild or
moderately severe GO had similar or worse
QOL impairment than patients suffering from
heart failure, pulmonary emphysema, or
diabetes mellitus. General questionnaires are,
however, not sensitive to some of the unique
problems experienced by patients with GO.4
Bradley et al5 investigated the QOL of GO
patients with 25 items of the National Eye
Institute Visual Function Questionnaire (NEI
VFQ-25). NEI VFQ-25 includes many items that
are relevant to GO patients; however, it lacks
items on other issues that are important to
evaluate the QOL of GO patients, such as
altered appearance and ocular discomfort.5
Terwee et al6 developed a Dutch language GO
QOL instrument and proved it to be a reliable
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instrument in Dutch GO patients. They used the QOL
questionnaire to evaluate the change in QOL score
associated with clinical improvement after different
treatment modalities.7 Park et al8 used the modified and
translated GO-specific QOL survey in Australians. This
was the first time that the questionnaire was applied to
an English-speaking population, and the results showed
significant correlation between impaired QOL score and
disease severity.
In this study, we translated the GO-specific QOL
survey into Korean and used the questionnaire in Korean
GO patients. The purpose of this study was to assess
GO-specific QOL in Korean patients and to determine
the correlation of GO-specific QOL scores with disease
severity and activity.
Materials and methods
Study design and recruitment of participants
After approval from the Institutional Review Board at
Yonsei University College of Medicine, informed consent
was obtained from all participants. This cross-sectional
study included 98 patients with GO who were followed
at the Department of Ophthalmology, Yonsei University
College of Medicine between January and December
2010. The inclusion criteria were the presence of typical
eye symptoms and signs in a patient with autoimmune
Graves’ disease. The patients who have ophthalmic
diseases such as cataract, age-related macular
degeneration, glaucoma, corneal opacity and so on that
could affect the QOL were excluded. Clinical data
collected include complete ophthalmic investigations,
autoimmune Graves’ disease progress and medication
history, ophthalmological data of visual acuity,
intraocular pressure, diplopia tests such as binocular
single vision test or Hess screen, and proptosis
measurement by Hertel exophthalmometer. All clinical
observations and objective measurements were
consistently performed by one ophthalmologist (JS Yoon).
Outcome variable
Grave’s Ophthalmopathy specific Quality of Life survey
(GO-QOL survey) provided by Terwee et al7 from the
Netherlands was translated into Korean language. It has
16 questions divided into two sections; visual
functioning and appearance. The GO-QOL survey was
converted into QOL scores in which 0 corresponds to
worst and 100 to no disturbance in visual function and
appearance. The same method was used as previously
described by Terwee et al.7 We gave the translated GO
QOL survey and informed consent to almost all
patients who visited our oculoplastic clinic. Patients
self-administered the questionnaire during outpatient
clinic consultations.
Independent variable
Clinical activity was evaluated by one ophthalmologist
(JS Yoon) and was described using a Clinical Activity
Score (CAS) based on seven signs of inflammation of the
orbit.9 The grading scale was from 0 to 7. GO patients
were divided into three overall groups according to CAS
grades: 0–1, 2–3, and 4–7 for statistical analysis. Patients
with CAS 4 or more were considered as having clinically
active inflammation. The severity of GO was described
by the modified NOSPECS score obtained by adding
NOSPECS grades for each of soft-tissue involvement,
proptosis, extraocular muscle (EOM) involvement, lid
retraction, site difference, corneal defect, and optic nerve
compression. We quoted the modified NOSPECS
classification that was used in the publication of Echstein
et al10 as a basic concept, and added the grade 1 of EOM
involvement if there was a limitation of motion at
extreme gaze to make the grade of EOM involvement in
numerical order.
The range of modified NOSPECS scores was from 0
(normal) to 17 (most severe). GO was divided into three
grades based on the modified NOSPECS score: 0–3, 4–7,
and 7–17, which correspond to mild, moderate, and
severe disease categories, respectively. To evaluate
internal consistency and reliability, the Cronbach’s
alphas of two sections were calculated.
Statistical analysis
Descriptive statistics of the study population were
reported. Associations between QOL score and the
modified NOSPECS score or CAS were analysed by
regression analysis using Pearson’s correlation and
multiple regression analysis. Adjusted means of QOL
score of visual functioning and appearance were
calculated to assess the relationship of the modified
NOSPECS score and CAS. To determine which
component (soft-tissue involvement, proptosis, EOM
involvement, lid retraction, site difference, corneal defect,
or optic nerve compression) of the modified NOSPECS
score was the strongest predictor of QOL score, adjusted
means of QOL score were calculated and adjusted for the
other variables mentioned above. Statistical calculation
was done using the software program SPSS version 18.0
(SPSS Inc., Chicago, IL, USA). In all analyses, we
determined two-sided P-values and considered a P-value
less than 0.05 to be significant.
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Results
GO-QOL questionnaires were distributed to all 98
patients. The surveys of 12 patients contained one
unanswered question, while three patients had two or
more unanswered questions.
The clinical characteristics and demographic details of
the patient population are shown in Table 1. The 98
patients included 79 women and 19 men with a mean age
of 40.7 years. Eighty patients took anti-thyroid medi-
cations. Seven patients received radioiodine treatment
and five patients had thyroidectomy. The mean CAS was
2.1, and the mean modified NOSPECS score was 4.4. The
number of active GO patients, assuming active GO to be
in participants with CAS at least 4, was 19 (19.4%).
The frequencies of responses to each of the questions
are shown in Table 2. In all, 71.4% of the patients felt that
GO interfered with their visual function in some way and
95.9% patients felt their altered appearance interfered
with psychosocial functioning. The most frequently
limited activities were reading (59.2%), doing something
they wanted to do (53.1%), watching TV (49.0%), and
doing hobbies or pastimes (42.9%). The majority of
participants perceived altered appearance (91.8%) and
impaired self-confidence (70.4%).
Cronbach’s alphas were 0.90 for visual functioning and
0.88 for appearance. The consistency and reliability of the
questionnaire were both well preserved, compared with
Cronbach’s alphas of the Dutch GO-QOL survey made
by Terwee et al.6
The mean QOL score of visual function-associated
questionnaire was 73.7±26 (mean±SD). The mean QOL
score of appearance-related questionnaire was 61.9±26.
The mean QOL score of total questionnaire was 67.8±22.
The modified NOSPECS score and CAS on QOL score
Regression analysis showed that the QOL scores of visual
functioning were significantly negatively correlated with
Table 1 Characteristics of patients with Graves’ ophthalmo-
pathy at the time of the survey
GO patients N¼ 98
Age (years) 40.7 (15–72)
Gender (male/female) 19/79
Smokers 17 (17.7%)
DM 5 (5.1%)
HTN 9 (9.2%)
Other autoimmune disease 5 (5.1%)
Family history of thyroid disease 18 (18.4%)
Treatment of thyroid dysfunction
Anti-thyroid medication 80/98 (81.6%)
Radioiodine therapy 7/98 (7.1%)
Thyroidectomy 5/98 (5.1%)
Clinical feature of GO patients
Clinical activity score (CAS) 2.1±1.6 (0–7)a
The modified NOSPECS score 4.4±2.7 (0–17)a
Active GO (CASZ4) 19 (19.4%)
Optic nerve involvement 7 (7.1%)
Abbreviations: DM, diabetes mellitus; HTN, hypertension.
aMean±SD (range).
Table 2 Frequencies of responses from questions on visual functioning and appearance
Visual functioning
Limitation in carrying out the following activity
Severely limited
(%)
Little limited
(%)
Not limited
(%)
Missing response
(%)
Q1. Riding a bicyclea 5.1 5.1 52.0 5.1
Q2. Drivingb 6.1 24.5 31.6 5.1
Q3. Moving around the house 0 16.3 81.6 2.0
Q4. Walking outdoors 6.1 23.5 68.4 2.0
Q5. Reading 16.3 42.9 39.8 1.0
Q6. Watching TV 9.2 38.8 51.0 1.0
Q7. Hobbies or pastimes 9.2 30.6 57.1 3.1
Q8. Hindered from doing something they wanted to do 19.4 33.7 43.9 3.1
Appearance Very much (%) A little (%) No (%) Missing response (%)
Q9. Changed appearance 56.1 35.7 8.2 0.0
Q10. Stared in the streets 15.3 42.9 41.8 0.0
Q11. People react unpleasantly 2.0 25.5 72.5 0.0
Q12. Influence on self confidence 28.6 41.8 29.6 0.0
Q13. Socially isolated 4.0 22.4 73.6 0.0
Q14. Influence on making friends 9.2 26.5 64.3 0.0
Q15. Appear less often on photos than before 38.8 31.6 29.6 0.0
Q16. Mask changes in your appearance 23.5 31.6 44.9 0.0
aCannot ride a bicycle: 32.7%.
bNo drivers’ licence: 32.7%.
Cronbach’s alpha: 0.90 for visual functioning/0.88 for appearance.
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age (Pearson coefficient¼0.254, P¼ 0.012), the
modified NOSPECS score (Pearson coefficient¼0.410,
Po0.001), and CAS (Pearson coefficient¼0.266,
P¼ 0.008) (Figure 1). The QOL scores of appearance and
total QOL scores were also negatively correlated with the
modified NOSPECS score (Pearson coefficient¼0.347,
P¼ 0.001) and CAS (Pearson coefficient¼ 0.382, Po0.01)
in Pearson Correlation analyses (Table 3).
Multivariate linear regression analysis with
adjustment for age and gender showed that patients
belonging to the more severe disease category based
on the modified NOSPECS score showed significantly
less mean QOL scores of visual function (Po0.05) and
appearance (Po0.05) than those in the mild disease
category (Figure 1a). Similar trends were observed when
the effect of CAS on QOL score was analysed. Patients
belonging to the more active disease category based on
CAS showed significantly less mean QOL scores of visual
function (Po0.05) and appearance (Po0.05) than those
with mild disease (Figure 1b).
Soft-tissue involvement, proptosis and EOM involvement
in the modified NOSPECS score on QOL score
The associations between each component of the
modified NOSPECS classification such as soft-tissue
involvement, proptosis, or EOM involvement and the
QOL scores are shown in Figure 2. Multivariate linear
regression analysis with adjustment for age, gender, and
each component of the modified NOSPECS score showed
that worse soft-tissue involvement and proptosis was
significantly associated with decreased QOL scores of
appearance (P¼ 0.011 and 0.034 respectively) (Figures 2a
and b), whereas the degree of EOM involvement was
correlated with decreased QOL scores of visual
functioning (P¼ 0.001, Figure 2c). Other components of
Figure 1 The effect of (a) modified NOSPECS scores and (b) clinical activity score on QOL scores of visual functioning and
appearance in multivariate linear regression analysis adjusted for age and gender. Vertical line ranges from maximum to minimum
value. Bold square presents one standard error range. The number represents the mean of adjusted QOL scores for each section. CAS,
clinical activity score; QOL, quality of life.
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the modified NOSPECS classification such as lid
retraction, site difference, corneal defect, and optic nerve
compression showed no significant association with each
QOL score.
Discussion
GO influences patients’ activities of daily lives such as
reading, watching television, and pastimes, as well as
dysfunction of social role and impaired self-image
because of the altered appearance. Previous studies
reported a low correlation between generic QOL survey
and the severity of disease.4,5,11 Our group published on
the QOL of GO patients measured with the Korean
version of the 36-item Short-Form General Health Survey
(SF-36) questionnaire.11 According to that study, the QOL
of Korean patients with threatened vision or significant
diplopia was significantly low. However, overall scores
of QOL on the SF-36 were not highly correlated with the
severity of disease, probably because the generic QOL
questionnaires such as Medical Outcome Study, SF-36,
and NEI VFQ were not generated specifically for GO.
The GO-specific QOL survey provided by Terwee et al,7
characterized well the GO-specific conditions that impair
the QOL. In this study, we found that GO-QOL scores of
Korean patients were significantly correlated with
disease severity and inflammatory activity measured by
the modified NOSPECS score and CAS, respectively. In
addition, as the Cronbach alphas of the Korean language
survey used in this study were comparable with those of
the Dutch GO-QOL survey (visual functioning, 0.86 in
reference vs 0.90 in this study; and appearance, 0.82 in
reference vs 0.88 in this study),6 it is assumed that the
validity and internal consistency of the Korean language
questionnaire were also well preserved.
The mean QOL scores measured in this study were
much higher than those measured in the Dutch and
Australian GO-QOL survey (visual functioning, 54.7 in
Dutch survey, 59.0 in Australian survey and 73.7 in this
study; appearance, 60.1 in Dutch survey, 54.5 in
Australian survey and 61.9 in this study). The difference
of QOL scores between these studies might be associated
with the different characteristics of the enrolled patients.
The mean CAS was 2.6 in the Dutch survey and 2.1 in
this study, meaning that the Korean GO patients who
were enrolled in this study had a milder form of GO than
the patients enrolled in the Dutch survey. The GO
severity of each survey group could not be compared
because the three surveys each had used different
methods for calculating the GO severity. Another
possible cause of the different QOL score might be the
ethnic difference. It is well known that the prevalence
and clinical features of GO have racial difference.12,13 Tsai
et al14 reported that exophthalmos values of patients withTa
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Chinese Graves’ disease in Taiwan tend to be lower than
those of Caucasians and black-American people. The
ethnic characteristics of GO, which appears to be milder
in Asians than Caucasians, could attribute to the
difference between the QOL scores.
The mean QOL score of visual functioning was
correlated with age. Older participants gave low scores
on visual functioning than younger participants (Pearson
coefficient¼0.254, P¼ 0.012). This tendency was also
observed in the Australian GO-QOL survey. Park et al8
suggested that older participants are more concerned
about limitations in vision-related tasks and less
concerned about changes in appearance. However, there
is also a possibility that actual visual difficulties resulting
from the aging process could have a negative influence
on the QOL scores of visual functioning. To confirm the
association of the modified NOSPECS score and CAS
with QOL scores, effects of age and gender were
Figure 2 The effect of (a) soft-tissue involvement, (b) proptosis, and (c) extraocular muscle involvement by modified NOSPECS score
on QOL scores of visual functioning and appearance in multivariate linear regression analysis adjusted for age, gender, and each
component of the modified NOSPECS score. EOM, extraocular muscle; QOL, quality of life.
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controlled for using multivariate linear regression
analysis. As shown in Figure 1, CAS and the modified
NOSPECS score still had statistical significant
associations with QOL scores.
The mean QOL scores showed a significant correlation
with CAS, which is well known and currently used as a
clinical parameter of disease activity. When patients are
in the active phase of GO, the inflammatory symptoms
and signs such as swelling of preorbital area, injection of
eye ball and retro orbital pain associated with eye
movement can have negative influence on cosmesis and
also induce decreased visual function, both of which
make patients nervous and frustrated, deteriorating
psychosocial well-being.
Interestingly, visual functional scores were strongly
correlated with EOM involvement scores, whereas
appearance scores were significantly correlated with
soft-tissue involvement and proptosis scores. To our
knowledge, this is the first report of the association
between the specific parameters of severity and GO-QOL
scores. As the patients exhibit a heterogeneous clinical
course, GO is very difficult to manage. Unfortunately the
tools to evaluate patients’ status in the outpatient
clinic have been limited thus far. The GO-QOL
would be helpful for patient follow-up and useful in
making decisions about management in clinically
heterogeneous GO. Either visual functioning
questionnaires or appearance questionnaires can be,
respectively, applied to corresponding patients with
muscle-predominant disease or cosmetically disfigured
patients with soft-tissue involvement or proptosis in the
outpatient clinic.
Our study has some limitations. First, this was a cross-
sectional study, which makes it hard to clarify the causal
relationship. Second, our results were derived from a
relatively specific group of patients seen at a single
academic institution, and the condition of patients in our
clinic could be different from that of patients in the
community setting. Third, the fact that GO severity
and activity were observed by one clinician could be
good for reliability; however, this could create systemic
bias.
Nowadays, GO is understood not only as a vision-
threatening disease but also a psychosocially debilitating
disease. Such limitations to daily living and impaired
self-confidence caused by GO could be improved after
appropriate treatment. However, it is difficult to
determine how we can evaluate these illnesses and when
to start treatment. The GO-specific QOL survey is a
simple and easily applicable item that can be used in the
clinic, and could be a valuable clinical parameter that
helps in the evaluation of GO activity and severity,
allowing treatment planning and measurement of the
efficacy of treatment.
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